



Regulatory Features of the Spinocerebellar Ataxia Type 2 Gene *ATXN2* Promoter and 3'-UTR

Daniel R. Scoles

Stephen T. Hansen

Lance T. Pflieger

Stefan M. Pulst



Spinocerebellar Ataxia Type 2 (SCA2)

- SCA2 is a polyglutamine disorder caused by *ATXN2* mutation.
- Gait ataxia, frontal executive dysfunction, slow saccades, and parkinsonism.
- Age of onset is characterized by anticipation where CAG22-23 is normal and CAG>32 causes disease.
- Characterized by Purkinje cell death.
- Gain of normal function (Duvick et al., *Neuron* 2010).

Ataxin 2 regulates mRNA, Ca²⁺ movement and endocytosis

RNA Binding Proteins

- | | |
|-------------|--|
| A2BP1/Fox 1 | Shibata et al., HMG 9:1303-13; 2000 |
| PABP1 | Nonhoff et al., PNAS 98:4409-13; 2001 |
| DDX6 | Nonhoff et al., MBC 18:1385-96; 2007 |
| TDP-43 | Elden et al., Nature 466:1069-75; 2010 |

Endocytosis and EGFR Function

- | | |
|-------------|--|
| Endophilins | Nonis et al., Cell Signal 20:1725-39; 2009 |
|-------------|--|

Calcium Movement

- | | |
|------|--|
| IP3R | Liu et al., J Neurosci 29:9148-62;2009 |
|------|--|


Hypothesis

Reduction of ataxin-2 expression or mRNA stability provides a therapeutic avenue for SCA2.


- SCA2 phenotype is worse in patients homozygous for the disease allele (Ragothaman and Muthane, 2008).
- SCA2 phenotype is worse in homozygous vs heterozygous *ATXN2* transgenic mice (Huynh et al., 2000).
- *ATXN2* knockout mice are obese (Kiehl et al., 2006; Huynh et al., 2009).
- Reversibility of SCA1&3 transgenic mouse phenotype (Zu et al., 2004; Boy et al., 2009).
- shRNA injection in brains of *ATXN1* mouse improved phenotype (Xia et al., 2004).

pGL2-ATXN2-Luc


ATXN2-Luciferase Expression Construct



ATXN2 promoter deletions



ATXN2 Interstitial Promoter Deletions





Deletion of an ETS family transcription factor binding site reduced ATXN2-luc expression



100% match for an ETS family transcription factor element located on the *ATXN2* negative strand:

5'-CCGGAAGT-3'



+96 +103
ATXN2 ... ctccgacttccggtaaagag...
mCGA ... ctccgact**CGA**ggtaaagag...
d14 ... ctc-----gag...





EMSA supershift assays verified interactions with ETS family transcription factors ELF-2 and ETS-1



ATXN2-luc expression in mice




ATXN2-luc expression in excised tissues



Summary & Conclusions

- **New reporter system for studying *ATXN2* expression control.**
- **Inhibitory elements likely exist to control *ATXN2* expression.**
- **We identified a critical region in *ATXN2* where ETS factors act.**
- ***ATXN2-luc* was highly expressed in cerebellum.**



Acknowledgments

University of Utah
Department of Neurology

Warunee Dansithong

Khanh Thai

Stephen Hansen

Lance Pflieger

Stefan Pulst

University of Utah
Department of Oncological Sciences

Barbara Graves

University of Utah
Department of Oncological Sciences

Stephen Lessnick

Colleen Druzgal



Supported by National Institutes of Health grants
1RC4NS073009 & 5R01NS033123

ATXN2 3'-UTR Deletions

